Loading

JSM Nanotechnology and Nanomedicine

Nanostructured Lipid Carrier System for the Treatment for Skin Disease-A Review

Review Article | Open Access | Volume 5 | Issue 3

  • 1. Department of Pharmaceutics, JSS College of Pharmacy, India
+ Show More - Show Less
Corresponding Authors
Tejasa Upreti, Department of Pharmaceutics, JSS College of Pharmacy, Ootacamund, Jagadguru Sri Shivarathreeshwara University, Mysore, India
Abstract

Nanostructured lipid carrier is a novel delivery system that has shown great potential as an excellent carrier system. Skin disease treatment usually employs topical and systemic delivery with topical delivery being more preferred. The limitations of topical therapy are its lack of adherence to the application site and larger particle size of drug which makes it difficult for drugs to penetrate through the layers of skin. In Nanostructured lipid carrier formulations the drugs are in Nano range that are encapsulate in a lipid core which helps achieve localized and slow release over time. The advantage of loading drugs on nanostructured lipid carrier in terms of efficacy and formulation aspect is discussed in this review with the help of current research literary papers.

Keywords

Skin diseases,  NLC , Topical ,  Preparation methods , Techniques

Citation

Upreti T, Senthil V (2017) Nanostructured Lipid Carrier System for the Treatment for Skin Disease-A Review. JSM Nanotechnol Nanomed 5(3): 1059.

INTRODUCTION

Skin disease is one of the most common types of disease that affects human beings. Though rarely fatal these diseases not just hurts physically, its presence makes individuals disturb emotionally, isolated, lack in self-esteem and discomfort. With an average surface area of 1.6-2m2 and constituting about 15% of total body weight of an adult human, skin is considered as one of the largest organ of the body. It functions as a barrier and protects the underlying muscles, bones, ligaments and internal organs [1,2].

LAYERS OF SKIN

Skin can be divided into three layers:

Epidermis

The foremost barrier for external environment prevents pathogens from entering into the skin and causing infection [2]. Its cellular components includes a) keratinocytes- also known as basal cells since they are present on the basal layer of the skin and functions as a barrier for the environmental damage; b) melanocytes- melanin producing cells located in the stratum basale of skin and uvea of the eye; c) Langerhans cells- functions as antigen presenting cells; d) merkel cells- oval receptor cells that are associated with the sense of touch discrimination of shape and texture [2,3].

The epidermis consists of 4 sublayers: i) stratum corneumthe outermost layer composed mostly of corneocytes (non- living keratinocytes). It consists of dense network of keratin which makes it the toughest layer to penetrate for topical drug delivery; ii) stratum lucidum- is translucent under microscope and is a clear layer of dead keratinocytes cells; iii) stratum granulosumconsists of keratinocytes that have migrated from lower layer and appear granular; iv) stratum spinosum- or “pickle cell” layer. Keratinization begins in this sub layer. The basal layer or stratum basale consists of proliferating or non-proliferating keratinocytes. This layer also consists melanocytes, Langerhans cell and merkel cells [2-4]

Dermis

Dermis is present below the epidermis layer and is thick, fibrous and elastic imparting flexibility and strength to the skin [3], consist of sweat, oil glands, nerve ending, hair follicles, blood and lymph vessels. It maintains and repairs the skin [4].

Hypodermis

Hypodermis is the lowermost layer of the skin consisting of loose connective tissue, elastic fibres and cells such as fibroblasts, macrophages and adipocytes. It functions as energy reserve and insulator [4] (Figure 1 and Table 1).

Figure 1: Figure shows the Hypodermis layer of the skin consisting of loose connective tissue, elastic fibres and cells

Figure 1: Figure shows the Hypodermis layer of the skin consisting of loose connective tissue, elastic fibres and cells

Table 1: Table shows the Common skin diseases, causative agents, affected site and treatment

SN

Disease

Cause

Affected site

Symptoms

Treatment

Ref.

1

Scabies

Mites under skin

Anywhere on the body except face

Itching, red papules

Malathion or 5% permethrin lotion

[8,9]

2

Psoriasis

Immune- mediated hyperproliferation disorder, chronic inflammatory dermatitis

Plaque psoriasis (elbows, knee & sacrum); palmopustular (palms, soles); Flexural (auxillae, submammary)

Thick red rash covered with silvery scales

Topical- corticosteroids, vitamin D analogues, Tar based preparations, dithranol

Systemic- methotrexate, immunosuppressant, retinoids

[10]

3

Acne vulgaris

Chronic inflammation of pilosebaceous apparatus

Areas rich in sebaceous glands such as face, shoulders and trunk

Open comedones (dilated pore with a plug of keratin) or closed comedones (small cream coloured papules- whiteheads)

Benzoyl peroxide cream, tretinoin, antibiotics (tetracyclin, erythromycin, trimethoprim), anti androgen, retinoids, steroids, non drug therapies (excision, cryotherapy)

[11, 12, 13]

4

Cold sores

Herpes simplex virus fever, triggered by stress, sun or menstruation

mouth or nose

Small, painful, fluid filled blisters

Antiviral pills or creams

 

5

Vitiligo

Autoimmune disease associated with pernicious anemia, thyroid disease and Addison’s disease

Hands, wrist, face and genitalia

Macules of pigment loss on the skin, in some cases hair may be depigmented

Potent topical steroids and uv phototherapy

[14]

6

Melasma

Pregnancy

Cheeks, nose, forehead and chin

Tan or brown patches

Prescription creams and over the counter products

[15]

New improvements are being developed for the proper delivery of the medications for the treatment of skin diseases [16]. As we know that only developing new therapies is not enough for the drugs to work appropriately, the therapies may look very efficient theoretically and while conducting in vitro studies but the dosage regimen when applied may show different result in vivo. Various approaches can be made to enhance the efficiency  of the very drug used in those therapies either by increasing its solubility in the body or absorption at the site by using different techniques [17].

One of such approach can be development of suitable carriers for the drug. Nanostructured lipid carrier (NLC) is a novel technology that can be used for the treatment of skin diseases. Numerous researches are on-going for developing drug loaded NLC delivery for the treatment of skin disorders. Commonly systemic and topical medications are used as a treatment method, systemic delivery have higher potential of adverse effects compared to systemic delivery. Patients are more complaint and satisfied with topical delivery. Carrier system for the drugs that makes it more soluble and absorbable is being studied like lipid nanoparticles where the drugs are dissolved in lipids. Lipid nanoparticles have shown promising results and progress are being made in this novel drug delivery system [17,18].

NANOSTRUCTURED LIPID CARRIER

Lipid nanoparticles are colloidal carriers which have shown a high potential as a suitable drug carrier because of their potential to increase solubility and improve bioavailability of poorly water soluble or lipophilic drugs and extensive research have been conducted on it in the recent years [17]. It can be mainly divided into solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC). Prior to this, various other lipid carriers like liposomes, micro and nanoemulsions, nanocapsules, nanosponges and polymeric nanoparticles were used for the effective delivery of poorly soluble drugs which had its own drawbacks such as rapid degradation by the pH and enzymes present in the GIT, stability problems during storage, organic solvent residues, toxicity from polymers, etc. Then SLN were developed as an alternate carrier scheme to liposomes, emulsions and polymeric nanoparticles. The difference between SLN and NLC is that in SLN only solid lipid is used in which the drug is incorporated whereas in NLC the drug is incorporated in solid and liquid lipid mix which may give better sustained release characteristic to the formulation [19-22].

Many research conducted have found that drugs are more soluble in fluids lipid than in solid lipids. NLC is the second generation in lipid based nanoparticles and is reported to be better when compared to SLN [23,24].

Limitations of SLN • low drug load capacity

• Drug leakage/ expulsion during storage

• Unpredictable gelation tendency

• High water content of SLN dispersion

• Tendency for particle size growth

• Payload of hydrophilic drug is low

NLC formulation utilizes liquid lipids along with solid lipids that make it advantageous over SLN. But stability issues are still a point of concern for NLC formulators [25].

COMPONENTS

Solid lipids

Compounds with high melting point i.e. higher than 40 °C are used as solid lipid. It should be biodegradable and must be accepted by GRAS (generally recognized as safe) [26].

Eg: beeswax, tristearin, carnauba wax, percifac, stearic acid, cholesterol, apifil, cutina CP; cetyl palmitate

Liquid lipids

The liquid lipids used are digestable oils from natural sources. It must have well tolerated GRAS status and also accepted for human use [26].

Eg: cetiol V, miglyol, castor oil, oleic acid, davana oil, palm oil, olive oil

Emulsifying agent

Emulsifying agents are also called surfactants which lower the interfacial tension between two immiscible liquids or components. When used in small amount it enhances colloidal activity by decreasing rate of aggregation. Hydrophilic surfactants are mostly used. PEG added to the formulation prevents the uptake by reticuloendothelial system (RES) which results in the increase the circulation time of the drug. It should be biocompatible, cost effective, capable of being sterilized before application and nonirritating. Lipophilic or ampiphillic emulsifiers are used for the fabrication of NLCs [25].

Eg: miranol ultra, tween 80, poloxamer.

UV blockers

Added to prevent the damages caused by UV rays, lowering the risk of skin cancer.

Eg: avobenzone- absorbs UV-A radiation

Aqueous medium

Purified water is used.

To select the appropriate solid lipid, liquid lipid screening tests are carried out and the lipids in which the drug is most soluble is  selected. The selected lipids must be mixed in appropriate ratio to prepare stable NLC and for that purpose binary lipid phase selection is also done in which different ratios of selected solid lipid and liquid lipid are mixed and the best ratio is selected for preparing NLC [23,26] (Table 2)

Table 2: Screening tests carried out and the lipids in which the drug is most soluble is selected.

Ingredient Materials
Solid lipid Glyceryl behenate (compritol 888 ATO); glyceryl palmitostearate (percirol ATO 5); dynasan; fatty acid (eg: stearic acid); triglyceride (tristearin); steroids (cholesterol); waxes (cetyl palmitate)
Liquid lipid Medium chain triglycerides (miglyol 812); paraffin pil; 2- octyl dodecanol; propylene glycol dicaprylocaprate (labrafac); isopropyl myristate and squalene; palm oil Fatty acids: oleic acid; linoleic acid, decanoic acid
Hydrophilic emulsifier Pluronic F68 (poloxamer 188); Pluronic F127 (poloxamer 407); polysorbate 20; polysorbate 40; polysorbate 80; polyvinyl alcohol; Solutol HS15; trehalose; sodium deoxycholate; sodium glycocholate; sodium oleate; polyglycerol methyl glucose distearate
Lipophilic emulsifier Myverol 18-04K; span 20; Span 40; Span 60
Amphiphilic emulsifier Egg lecithin; soya lecithin; phosphatidylcholines; phosphatidylethanolamines; Gelucire 50/13

In Gaba B et al., different solid lipids and liquid lipids were screened and from the results obtained the drug was found to be most soluble in glyceryl monostearate and labrasol. The selected lipids at 6:4 ratio when stirred at 200 rpm at 85 °C for one hour gave appropriate binary lipid phase [25]. Kelidari HR, et al., reported that increase in oleic acid (liquid lipid) concentration increased the entrapment efficiency. While particles size shows no significant affect due to lipid concentration as reported by Souza LG, et al. [28]

PREPARATION

There are many techniques used for the preparation of nanostructured lipid carriers. The most commonly used techniques are high pressure homogenization, solvent emulsification method, supercritical fluid extraction of emulsion, ultrasonication or high speed homogenization and spray drying. The selection of method employed depends upon the drug, its solubility and stability, route of administration, etc [20,26,27].

High pressure homogenization technique

HPH technology has been widely popular and dependable technique for the production of lipid nanoparticles. It can also be used for large scale production of lipid nanocarriers. In this technique the fluids are pushed through a narrow gap of few micro ranges by high pressure (100- 200 bars). This reduces the particles size to submicron range. There are two homogenization processes developed i.e, hot and cold process. In both the process, prior to the application of homogenization the active pharmaceutical component is dissolved or dispersed in the melted lipids [27-30].

Hot homogenization process

The drug and the melted lipids is dispersed in the aqueous solution of same temperature containing emulsifier with the application of continual stirring using mixing device forming preemulsion which is then subjected to homogenization [31].

Cold homogenization technique

The process is similar to that of hot homogenization where the drug is mixed in the melted lipid and subsequently the mix is subjected to rapid cooling using liquid nitrogen or ice. This process has been developed to control the limitations with hot homogenization process like accelerated degradation due to elevated temperature of the lipid mix since cold homogenization reduces the duration of thermal exposure [32].

Gaba B, et al., reported that terbinafine loaded NLC prepared by high pressure homogenization method in which glyceryl monostearate, labrasol and pluronic F 127 used as solid lipid, liquid lipid and surfactant showed reduced fungal burden, better release profile and permeation when compared with marketed formulation [25].

Microemulsion technique

The microemulsion is prepared at a temperature above the melting point of the lipids. The lipids are heated at a temperature above its melting point and a combination of water, co-surfactant(s) and the surfactant is heated to the same temperature as the lipids and added to the lipid melt with mild stirring. Then the microemulsion is dispersed in cold aqueous medium consisting of water under mild stirring. This dispersion in cold aqueous medium leads to rapid recrystallization of the oil droplets [33-35]\

Solvent emulsification-evaporation technique

The hydrophobic drug and lipophilic material were dissolved in organic solvent and is further mixed with an aqueous phase using high speed homogenizer then the resultant coarse emulsion was immediately passed through the microfluidizer. Upon evaporation of the organic solvent by continuous stirring lipids precipitates from the aqueous medium to form nanoparticles dispersion. No thermal stress is applied which makes this method suitable for heat sensitive drugs. Particle size is determined by the concentration of lipid in organic phase; smaller the lipid load (5%) smaller will be particle size [36].

High shear homogenization or ultrasonication technique

Drug is mixed with the lipid phase heated and simultaneously the aqueous surfactant solution is heated to the same temperature. Then the heated aqueous phase is poured into the lipid mixture using magnetic stirrer forming pre emulsion. Ultrasonication was applied to the pre emulsion using probe sonicator with water bath (at 0 °C). After ultrasonication the product is passed through 0.45 µm to remove impurities. The disadvantage of this process is the use of high amount of surfactant also it has stability issues associated with the inappropriate particle size distribution. But this process can easily be taken as the most attainable one since the instruments used are relatively more available in labs than compared to hot and cold homogenization [20].

Pinto MF, et al., reported that methotrexate loaded NLC using high shear homogenization combined with ultrasonication where witepsol S51, oleic acid and polysorbate 60 or 80 were used as solid lipid, liquid lipid and surfactant. The particle sizes obtained were below 300 nm which is suitable for topical delivery. Also the in vitro skin permeation studies showed higher skin penetration with methotrexate loaded NLC when compared with free drug formulation [37,41].

Melting dispersion method

In melting method, drug, solid lipid and an organic solvent is melted together and water phase is heated to the same temperature separately. The solid lipid melt containing drug is subsequently added to water phase followed by high speed stirring for few hours. The resulting mixture is cooled down to room temperature to yield nanoparticles [38].

Spray drying

In spray drying technique, hot gas is applied to liquid or viscous liquid to produce dry powder, though it is expensive it is considered cost effective method when compared to lyophilisation- another technique used for product having stability issues. It is a method of preference for thermo sensitive products as the products are exposed to elevated temperature for every short period of time. Lipid with melting point greater than 70 °C are suitable, lower than that makes them unsuitable as the high shear force and temperature makes them to aggregate.

LYOPHILLIZATION

Lyphillization follows the principle of sublimation where the water changes directly from the solid state (ice) to the gaseous state without passing through the liquid state. This procedure is done to preserve the product from chemical and physical degradation. Cryoprotectants such as mannitol, trehalose, sorbitol, glucose, sucrose are added to the product to protect it from high stress generated during lyophilisation process. It does not change the molecular structure of the product and is the most reliable drying process [24]

Tilmicosin was loaded in lipid nanoparticles including solid lipid nanoparticles, liquid lipid nanoparticles and lipid core nanocapsules. The tilmicosin NLC suspension was prepared by hot homogenization technique using compritol 888 ATO, sesame oil and poloxamer 407 and tween 80. The NLC prepared was lyophilized using mannitol as cryoprotectant. The lyophilized products showed better stability over long period of storage [39].

Many research have been done to showcase the potential of NLC using different preparation methods. Drugs have shown increase in their efficiency when loaded in NLC. V.M. Ghate et al., In a research conducted on tretinoin loaded NLC for topical delivery, formulations were made using microemulsion technique and hot probe sonication technique. Stearic acid, oleic acid and tween 80 & span 60 were used as solid lipid, liquid lipid and surfactant respectively. The results obtained from the two preparation techniques showed that the particle size of the NLC prepared by microemulsion technique was found greater (2156 nm approximately with PDI value 0.891) than the ones prepared by probe sonication technique (762 nm with PDI value 0.483). The release profile of both the techniques showed less percentage of drug release when compared with the commercially available tretinoin gel which is a desirable for topical preparation and indicates prolonged release of drug can be achieved. Also tretinoin loaded NLC gel showed no irritation after 7 days of repeated application which marketed gel showed irritation within 3 days of application.

CONCLUSION

Nanaostructured lipid carriers have great advantage over other lipid nanoparticles and have better loading capacity. Lipid carriers show good potential to deliver the drugs in effective manner and can be considered as a progress in the treatment of skin disease. The drugs are more soluble in these lipid system and delivery of drug over prolong period of time can be achieved which is one of the desirable property of topical delivery. Also the particle size of drug is small in NLC and topical penetration is found to be more. Though lipid carriers are advantageous and seem to be safe their potential for toxicity over a long period of usage time must be checked. From all the information gathered from recent relevant literature it can be concluded that NLC is an excellent carrier system for the delivery of drugs for treatment of skin disease.

REFERENCES

1. Iizuka H. Epidermal turnover time. J Dermatol Sci. 1994; 8: 215-217.

2. Tripathi KD. Essentials of medical pharmacology. Ind J Pharmacol. 1994; 26: 166.

3. Waugh A, Ross GA, Anatomy W. Physiology: In Health and Illness. 10th edn. Churchill Livinstone: Elsevier. 2006; 293-295.

4. Tortora GJ, Derrickson BH. Principles of anatomy and physiology. John Wiley & Sons. 2008.

5. Johnstone CC, Farley A, Hendry C. The physiological basics of wound healing. Nurs Stand. 2005; 19: 59-65.

6. Mohan H. Textbook of pathology. New Delhi: Jaypee brothers medical publishers. 2005.

7. James WD, Berger TG, Elston DM. Andrews’ Diseases of the Skin: Clinical Dermatology, 11th edn. Philadelphia: Saunders Elsevier. 2011.

8. Mounsey KE, McCarthy JS. Treatment and control of scabies. Current opinion in infectious diseases. 2013; 26: 133-139.

9. Hengge UR, Currie BJ, Jäger G, Lupi O, Schwartz RA. Scabies: a ubiquitous neglected skin disease. Lancet Infect Dis. 2006; 6: 769-779.

10. Feldman SR, Horn EJ, Balkrishnan R, Basra MK, Finlay AY, McCoy D, et al. Council IP. Psoriasis: improving adherence to topical therapy. J Am Acad Dermatol. 2008; 59: 1009-1016.

11. Williams HC, Dellavalle RP, Garner S. Acne vulgaris. The Lancet. 2012; 379: 361-372.

12. Leyden JJ. A review of the use of combination therapies for the treatment of acne vulgaris. J Am Acad Dermatol. 2003; 49: S200-210.

13. Haider A, Shaw JC. Treatment of acne vulgaris. Jama. 2004; 292: 726- 735.

14. Cui J, Shen LY, Wang GC. Role of hair follicles in the repigmentation of vitiligo. J Invest Dermatol. 1991; 97: 410-416.

15. Piamphongsant T. Treatment of melasma: a review with personal experience. Int J Dermatol. 1998; 37: 897-903.

16. Ferreira M, Silva E, Barreiros L, Segundo MA, Costa Lima SA, Reis S. Methotrexate loaded lipid nanoparticles for topical management of skin- related diseases: Design, characterization and skin permeation potential. Int J Pharm. 2016; 14-21.

17. Khan S, Baboota S, Ali J, Khan S, Narang RS, Narang JK. Nanostructured lipid carriers: an emerging platform for improving oral bioavailability of lipophilic drugs. Int J Pharm Invest. 2015; 5: 182.

18. Mishra B, Patel BB, Tiwari S. Colloidal nanocarriers: a review on formulation technology, types and applications toward targeted drug delivery. Nanomedicine. 2010; 6: 9-24.

19. Müller RH, Souto EB, Radtke M. Nanostructured Lipid Carriers: A Novel Generation of Solid Lipid Drug Carriers Pharm Techn Europe. 2005; 17: 45-50.

20. Naseri N, Valizadeh H, Zakeri-Milani P. Solid lipid nanoparticles and nanostructured lipid carriers: structure, preparation and application. Advanced pharmaceutical bulletin. 2015; 5: 305.

21. Severino P, Andreani T, Macedo AS, Fangueiro JF, Santana MH, Silva AM, et al. Current State of-Art and New Trends on Lipid Nanoparticles (SLN and NLC) for Oral Drug Delivery. J Drug Deliv. 2012; 2012: 750891.

22. Puglia C, Bonina F. Lipid nanoparticles as novel delivery systems for cosmetics and dermal pharmaceuticals. Expert Opin Drug Deliv. 2012; 9: 429-441.

23. Katouzian I, Esfanjani AF, Jafari SM, Akhavan S. Formulation and application of a new generation of lipid nano-carriers for the food bioactive ingredients. Trends Food Sci Technol. 2017; 68: 14-25.

24. Kaur S, Nautyal U, Singh R, Singh S, Devi A. Nanostructure Lipid Carrier (NLC): the new generation of lipid nanoparticles. Asian Pac J Health Sci. 2015; 2: 76-93.

25. Gaba B, Fazil M, Khan S, Ali A, Baboota S, Ali J. Nanostructured lipid carrier system for topical delivery of terbinafine hydrochloride. Bulletin Faculty of Pharmacy, Cairo University. 2015; 53: 147-159.

26. Jenning V, Thünemann AF, Gohla SH. Characterisation of a novel solid lipid nanoparticle carrier system based on binary mixtures of liquid and solid lipids. Int J Pharm. 2000; 199: 167-177.

27. Uner M. Preparation, characterization and physicochemical properties of Solid Lipid Nanoparticles (SLN) and Nanostructured Lipid Carriers (NLC): Their benefits as colloidal drug carrier systems. Pharmazie. 2006; 61: 375-386.

28. Souza LG, Silva EJ, Martins AL, Mota MF, Braga RC, Lima EM, et al. Development of topotecan loaded lipid nanoparticles for chemical stabilization and prolonged release. Eur J Pharm Biopharm. 2011; 70: 189-196.

29. Hu FQ, Jiang SP, Du YZ, Yuan H, Ye YQ, Zeng S. Preparation and characterization of stearic acid nanostructured lipid carriers by solvent diffusion method in an aqueous system. Colloid Surf B Biointerfaces. 2005; 45: 167-173.

30. Schwarz C, Mehnert W, Lucks JS, Muller RH. Solid lipid nanoparticles (SLN) for controlled drug delivery: I. Production, characterization and sterilization. J Control Release. 1994; 30: 83-96.

31. Liedtke S, Wissing S, Muller RH, Mader K. Influence of high pressure homogenisation equipment on nanodispersions characteristics. Int J Pharm. 2000; 196: 183-185.

32. Lippacher A, Muller RH, Mader K. Preparation of semisolid drug carriers for topical application based on solid lipid nanoparticles. Int J Pharm. 2001; 214: 9-12.

33. Gasco MR. Solid lipid nanospheres from warm micro-emulsions. Pharm Technol Eur. 1997; 9: 52-58.

34. Boltri L, Canal T, Esposito PA, Carli F. Lipid nanoparticles: evaluation of some critical formulation parameters. Proc Int Symp Control Release Bioact Mater. 1993; 20: 346-347.

35. Dianrui Zhang, Tianwei Tan, Lei Gao. Preparation of oridonin-loaded solid lipid nanoparticles and studies on them in vitro and in vivo. Nanotechnol. 2006; 17: 5821.

36. Pinto MF, Moura CC, Nunes C, Segundo MA, Lima SA, Reis S. A new topical formulation for psoriasis: development of methotrexateloaded nanostructured lipid carriers. Int J Pharm. 2014; 477: 519-526.

37. Reithmeier H, Hermann J, Gopferich A. Lipid microparticles as a parenteral controlled release device for peptides. J Control Release. 2001; 73: 339-350.

38. Al-Qushawi A, Rassouli A, Atyabi F, Peighambari SM, EsfandyariManesh M, Shams GR, et al. Preparation and Characterization of Three Tilmicosin-loaded Lipid Nanoparticles: Physicochemical Properties and in-vitro Antibacterial Activities. IJPR. 2016; 15: 663.

39. Ghate VM, Lewis SA, Prabhu P, Dubey A, Patel N. Nanostructured lipid carriers for the topical delivery of tretinoin. Eur J Pharm Biopharm. 2016; 108: 253-261.

40. Gupta M, Vyas SP. Development, characterization and in vivo assessment of effective lepidic nanoparticles for dermal delivery of fluconazole against cutaneous candidiasis. Chem Phys Lipids. 2012; 165: 454-461.

41. Agrawal Y, Petkar KC, Sawant KK. Development, evaluation and clinical studies of Acitretin loaded nanostructured lipid carriers for topical treatment of psoriasis. Int J Pharm. 2010; 401: 93-102.

42. Allemann E, Gurny R, Doelker E. Drug-loaded nanoparticles: preparation methods and drug targeting issues. Eur J Pharm Biopharm. 1993; 39: 173-191

Upreti T, Senthil V (2017) Nanostructured Lipid Carrier System for the Treatment for Skin Disease-A Review. JSM Nanotechnol Nanomed 5(3): 1059.

Received : 04 Nov 2017
Accepted : 28 Nov 2017
Published : 30 Nov 2017
Journals
Annals of Otolaryngology and Rhinology
ISSN : 2379-948X
Launched : 2014
JSM Schizophrenia
Launched : 2016
Journal of Nausea
Launched : 2020
JSM Internal Medicine
Launched : 2016
JSM Hepatitis
Launched : 2016
JSM Oro Facial Surgeries
ISSN : 2578-3211
Launched : 2016
Journal of Human Nutrition and Food Science
ISSN : 2333-6706
Launched : 2013
JSM Regenerative Medicine and Bioengineering
ISSN : 2379-0490
Launched : 2013
JSM Spine
ISSN : 2578-3181
Launched : 2016
Archives of Palliative Care
ISSN : 2573-1165
Launched : 2016
JSM Nutritional Disorders
ISSN : 2578-3203
Launched : 2017
Annals of Neurodegenerative Disorders
ISSN : 2476-2032
Launched : 2016
Journal of Fever
ISSN : 2641-7782
Launched : 2017
JSM Bone Marrow Research
ISSN : 2578-3351
Launched : 2016
JSM Mathematics and Statistics
ISSN : 2578-3173
Launched : 2014
Journal of Autoimmunity and Research
ISSN : 2573-1173
Launched : 2014
JSM Arthritis
ISSN : 2475-9155
Launched : 2016
JSM Head and Neck Cancer-Cases and Reviews
ISSN : 2573-1610
Launched : 2016
JSM General Surgery Cases and Images
ISSN : 2573-1564
Launched : 2016
JSM Anatomy and Physiology
ISSN : 2573-1262
Launched : 2016
JSM Dental Surgery
ISSN : 2573-1548
Launched : 2016
Annals of Emergency Surgery
ISSN : 2573-1017
Launched : 2016
Annals of Mens Health and Wellness
ISSN : 2641-7707
Launched : 2017
Journal of Preventive Medicine and Health Care
ISSN : 2576-0084
Launched : 2018
Journal of Chronic Diseases and Management
ISSN : 2573-1300
Launched : 2016
Annals of Vaccines and Immunization
ISSN : 2378-9379
Launched : 2014
JSM Heart Surgery Cases and Images
ISSN : 2578-3157
Launched : 2016
Annals of Reproductive Medicine and Treatment
ISSN : 2573-1092
Launched : 2016
JSM Brain Science
ISSN : 2573-1289
Launched : 2016
JSM Biomarkers
ISSN : 2578-3815
Launched : 2014
JSM Biology
ISSN : 2475-9392
Launched : 2016
Archives of Stem Cell and Research
ISSN : 2578-3580
Launched : 2014
Annals of Clinical and Medical Microbiology
ISSN : 2578-3629
Launched : 2014
JSM Pediatric Surgery
ISSN : 2578-3149
Launched : 2017
Journal of Memory Disorder and Rehabilitation
ISSN : 2578-319X
Launched : 2016
JSM Tropical Medicine and Research
ISSN : 2578-3165
Launched : 2016
JSM Head and Face Medicine
ISSN : 2578-3793
Launched : 2016
JSM Cardiothoracic Surgery
ISSN : 2573-1297
Launched : 2016
JSM Bone and Joint Diseases
ISSN : 2578-3351
Launched : 2017
JSM Bioavailability and Bioequivalence
ISSN : 2641-7812
Launched : 2017
JSM Atherosclerosis
ISSN : 2573-1270
Launched : 2016
Journal of Genitourinary Disorders
ISSN : 2641-7790
Launched : 2017
Journal of Fractures and Sprains
ISSN : 2578-3831
Launched : 2016
Journal of Autism and Epilepsy
ISSN : 2641-7774
Launched : 2016
Annals of Marine Biology and Research
ISSN : 2573-105X
Launched : 2014
JSM Health Education & Primary Health Care
ISSN : 2578-3777
Launched : 2016
JSM Communication Disorders
ISSN : 2578-3807
Launched : 2016
Annals of Musculoskeletal Disorders
ISSN : 2578-3599
Launched : 2016
Annals of Virology and Research
ISSN : 2573-1122
Launched : 2014
JSM Renal Medicine
ISSN : 2573-1637
Launched : 2016
Journal of Muscle Health
ISSN : 2578-3823
Launched : 2016
JSM Genetics and Genomics
ISSN : 2334-1823
Launched : 2013
JSM Anxiety and Depression
ISSN : 2475-9139
Launched : 2016
Clinical Journal of Heart Diseases
ISSN : 2641-7766
Launched : 2016
Annals of Medicinal Chemistry and Research
ISSN : 2378-9336
Launched : 2014
JSM Pain and Management
ISSN : 2578-3378
Launched : 2016
JSM Women's Health
ISSN : 2578-3696
Launched : 2016
Clinical Research in HIV or AIDS
ISSN : 2374-0094
Launched : 2013
Journal of Endocrinology, Diabetes and Obesity
ISSN : 2333-6692
Launched : 2013
Journal of Substance Abuse and Alcoholism
ISSN : 2373-9363
Launched : 2013
JSM Neurosurgery and Spine
ISSN : 2373-9479
Launched : 2013
Journal of Liver and Clinical Research
ISSN : 2379-0830
Launched : 2014
Journal of Drug Design and Research
ISSN : 2379-089X
Launched : 2014
JSM Clinical Oncology and Research
ISSN : 2373-938X
Launched : 2013
JSM Bioinformatics, Genomics and Proteomics
ISSN : 2576-1102
Launched : 2014
JSM Chemistry
ISSN : 2334-1831
Launched : 2013
Journal of Trauma and Care
ISSN : 2573-1246
Launched : 2014
JSM Surgical Oncology and Research
ISSN : 2578-3688
Launched : 2016
Annals of Food Processing and Preservation
ISSN : 2573-1033
Launched : 2016
Journal of Radiology and Radiation Therapy
ISSN : 2333-7095
Launched : 2013
JSM Physical Medicine and Rehabilitation
ISSN : 2578-3572
Launched : 2016
Annals of Clinical Pathology
ISSN : 2373-9282
Launched : 2013
Annals of Cardiovascular Diseases
ISSN : 2641-7731
Launched : 2016
Journal of Behavior
ISSN : 2576-0076
Launched : 2016
Annals of Clinical and Experimental Metabolism
ISSN : 2572-2492
Launched : 2016
Clinical Research in Infectious Diseases
ISSN : 2379-0636
Launched : 2013
JSM Microbiology
ISSN : 2333-6455
Launched : 2013
Journal of Urology and Research
ISSN : 2379-951X
Launched : 2014
Journal of Family Medicine and Community Health
ISSN : 2379-0547
Launched : 2013
Annals of Pregnancy and Care
ISSN : 2578-336X
Launched : 2017
JSM Cell and Developmental Biology
ISSN : 2379-061X
Launched : 2013
Annals of Aquaculture and Research
ISSN : 2379-0881
Launched : 2014
Clinical Research in Pulmonology
ISSN : 2333-6625
Launched : 2013
Journal of Immunology and Clinical Research
ISSN : 2333-6714
Launched : 2013
Annals of Forensic Research and Analysis
ISSN : 2378-9476
Launched : 2014
JSM Biochemistry and Molecular Biology
ISSN : 2333-7109
Launched : 2013
Annals of Breast Cancer Research
ISSN : 2641-7685
Launched : 2016
Annals of Gerontology and Geriatric Research
ISSN : 2378-9409
Launched : 2014
Journal of Sleep Medicine and Disorders
ISSN : 2379-0822
Launched : 2014
JSM Burns and Trauma
ISSN : 2475-9406
Launched : 2016
Chemical Engineering and Process Techniques
ISSN : 2333-6633
Launched : 2013
Annals of Clinical Cytology and Pathology
ISSN : 2475-9430
Launched : 2014
JSM Allergy and Asthma
ISSN : 2573-1254
Launched : 2016
Journal of Neurological Disorders and Stroke
ISSN : 2334-2307
Launched : 2013
Annals of Sports Medicine and Research
ISSN : 2379-0571
Launched : 2014
JSM Sexual Medicine
ISSN : 2578-3718
Launched : 2016
Annals of Vascular Medicine and Research
ISSN : 2378-9344
Launched : 2014
JSM Biotechnology and Biomedical Engineering
ISSN : 2333-7117
Launched : 2013
Journal of Hematology and Transfusion
ISSN : 2333-6684
Launched : 2013
JSM Environmental Science and Ecology
ISSN : 2333-7141
Launched : 2013
Journal of Cardiology and Clinical Research
ISSN : 2333-6676
Launched : 2013
Journal of Ear, Nose and Throat Disorders
ISSN : 2475-9473
Launched : 2016
JSM Ophthalmology
ISSN : 2333-6447
Launched : 2013
Journal of Pharmacology and Clinical Toxicology
ISSN : 2333-7079
Launched : 2013
Annals of Psychiatry and Mental Health
ISSN : 2374-0124
Launched : 2013
Medical Journal of Obstetrics and Gynecology
ISSN : 2333-6439
Launched : 2013
Annals of Pediatrics and Child Health
ISSN : 2373-9312
Launched : 2013
JSM Clinical Pharmaceutics
ISSN : 2379-9498
Launched : 2014
JSM Foot and Ankle
ISSN : 2475-9112
Launched : 2016
JSM Alzheimer's Disease and Related Dementia
ISSN : 2378-9565
Launched : 2014
Journal of Addiction Medicine and Therapy
ISSN : 2333-665X
Launched : 2013
Journal of Veterinary Medicine and Research
ISSN : 2378-931X
Launched : 2013
Annals of Public Health and Research
ISSN : 2378-9328
Launched : 2014
Annals of Orthopedics and Rheumatology
ISSN : 2373-9290
Launched : 2013
Journal of Clinical Nephrology and Research
ISSN : 2379-0652
Launched : 2014
Annals of Community Medicine and Practice
ISSN : 2475-9465
Launched : 2014
Annals of Biometrics and Biostatistics
ISSN : 2374-0116
Launched : 2013
JSM Clinical Case Reports
ISSN : 2373-9819
Launched : 2013
Journal of Cancer Biology and Research
ISSN : 2373-9436
Launched : 2013
Journal of Surgery and Transplantation Science
ISSN : 2379-0911
Launched : 2013
Journal of Dermatology and Clinical Research
ISSN : 2373-9371
Launched : 2013
JSM Gastroenterology and Hepatology
ISSN : 2373-9487
Launched : 2013
Annals of Nursing and Practice
ISSN : 2379-9501
Launched : 2014
JSM Dentistry
ISSN : 2333-7133
Launched : 2013
Author Information X